Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients.

Haibe-Kains B, Desmedt C, Di Leo A, Azambuja E, Larsimont D, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B, Maerevoet M, Vindevoghel A, Rouas G, Lallemand F, Durbecq V, Cardoso F, Salgado R, Rovere R, Bontempi G, Michiels S, Buyse M, Nogaret JM, Qi Y, Symmans F, Pusztai L, D'Hondt V, Piccart-Gebhart M, Sotiriou C.

Genom Data. 2013 Oct 1;1:7-10. doi: 10.1016/j.gdata.2013.09.001. eCollection 2013 Dec.

2.

Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by integrating the genomic grade index (GGI): new tools for ductal carcinoma in situ (DCIS).

Altintas S, Toussaint J, Durbecq V, Lambein K, Huizing MT, Larsimont D, Van Marck E, Vermorken JB, Tjalma WA, Sotiriou C.

Breast J. 2011 Jul-Aug;17(4):343-51. doi: 10.1111/j.1524-4741.2011.01091.x. Epub 2011 Jun 6.

PMID:
21645166
3.

Multifactorial approach to predicting resistance to anthracyclines.

Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B, Maerevoet M, Vindevoghel A, Rouas G, Lallemand F, Durbecq V, Cardoso F, Salgado R, Rovere R, Bontempi G, Michiels S, Buyse M, Nogaret JM, Qi Y, Symmans F, Pusztai L, D'Hondt V, Piccart-Gebhart M, Sotiriou C.

J Clin Oncol. 2011 Apr 20;29(12):1578-86. doi: 10.1200/JCO.2010.31.2231. Epub 2011 Mar 21.

PMID:
21422418
4.

HER2-positive circulating tumor cells in breast cancer.

Ignatiadis M, Rothé F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C, Metallo J, Kheddoumi N, Singhal SK, Michiels S, Veys I, Rossari J, Larsimont D, Carly B, Pestrin M, Bessi S, Buxant F, Liebens F, Piccart M, Sotiriou C.

PLoS One. 2011 Jan 10;6(1):e15624. doi: 10.1371/journal.pone.0015624.

5.

Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS).

Toussaint J, Durbecq V, Altintas S, Doriath V, Rouas G, Paesmans M, Bedard P, Haibe-Kains B, Tjalma WA, Larsimont D, Piccart M, Sotiriou C.

PLoS One. 2010 Aug 10;5(8). pii: e12100. doi: 10.1371/journal.pone.0012100.

6.

Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors.

McBride DJ, Orpana AK, Sotiriou C, Joensuu H, Stephens PJ, Mudie LJ, Hämäläinen E, Stebbings LA, Andersson LC, Flanagan AM, Durbecq V, Ignatiadis M, Kallioniemi O, Heckman CA, Alitalo K, Edgren H, Futreal PA, Stratton MR, Campbell PJ.

Genes Chromosomes Cancer. 2010 Nov;49(11):1062-9. doi: 10.1002/gcc.20815.

7.

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.

Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C.

Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10208-13. doi: 10.1073/pnas.0907011107. Epub 2010 May 17.

8.

Evaluation of the histological size of the sentinel lymph node metastases using RT-PCR assay: a rapid tool to estimate the risk of non-sentinel lymph node invasion in patients with breast cancer.

Veys I, Majjaj S, Salgado R, Noterman D, Schobbens JC, Manouach F, Bourgeois P, Nogaret JM, Larsimont D, Durbecq V.

Breast Cancer Res Treat. 2010 Dec;124(3):599-605. doi: 10.1007/s10549-009-0555-2. Epub 2009 Sep 25.

PMID:
19779817
9.

Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues.

Toussaint J, Sieuwerts AM, Haibe-Kains B, Desmedt C, Rouas G, Harris AL, Larsimont D, Piccart M, Foekens JA, Durbecq V, Sotiriou C.

BMC Genomics. 2009 Sep 10;10:424. doi: 10.1186/1471-2164-10-424.

10.

Eighteen months clinical experience with the GeneSearch breast lymph node assay.

Veys I, Durbecq V, Majjaj S, Schobbens JC, Noterman D, Sirtaine N, Martinez MD, Hertens D, Feoli F, Bourgeois P, Nogaret JM, Larsimont D.

Am J Surg. 2009 Aug;198(2):203-9. doi: 10.1016/j.amjsurg.2008.09.012. Epub 2009 Feb 27.

PMID:
19249740
11.

Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH.

Desmedt C, Sperinde J, Piette F, Huang W, Jin X, Tan Y, Durbecq V, Larsimont D, Giuliani R, Chappey C, Buyse M, Winslow J, Piccart M, Sotiriou C, Petropoulos C, Bates M.

Diagn Mol Pathol. 2009 Mar;18(1):22-9. doi: 10.1097/PDM.0b013e31818ebc69.

PMID:
19214112
12.

Clinical validation of a molecular assay for intra-operative detection of metastases in breast sentinel lymph nodes.

Martin Martinez MD, Veys I, Majjaj S, Lespagnard L, Schobbens JC, Rouas G, Filippov V, Noterman D, Hertens D, Feoli F, Bourgeois P, Durbecq V, Larsimont D, Nogaret JM.

Eur J Surg Oncol. 2009 Apr;35(4):387-92. doi: 10.1016/j.ejso.2008.05.008. Epub 2008 Jul 17.

PMID:
18639429
13.

Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.

Galmarini CM, Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, Di Leo A, Dumontet C.

Clin Cancer Res. 2008 Jul 15;14(14):4511-6. doi: 10.1158/1078-0432.CCR-07-4741.

14.

Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients.

Journe F, Durbecq V, Chaboteaux C, Rouas G, Laurent G, Nonclercq D, Sotiriou C, Body JJ, Larsimont D.

Breast Cancer Res Treat. 2009 Jun;115(3):523-35. doi: 10.1007/s10549-008-0094-2. Epub 2008 Jun 19.

PMID:
18563553
15.

A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer.

Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris A, Goss P, Sotiriou C, Erlander M, Sgroi D.

Clin Cancer Res. 2008 May 1;14(9):2601-8. doi: 10.1158/1078-0432.CCR-07-5026.

16.

[HER2 and topoisomerase II alpha: useful clinical markers in breast cancer].

Larsimont D, Durbecq V, Awada A, Di Leo A.

Bull Cancer. 2008 Mar;95(3):344-51. doi: 10.1684/bdc.2008.0596. Review. French.

17.

A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics.

Durbecq V, Ameye L, Veys I, Paesmans M, Desmedt C, Sirtaine N, Sotiriou C, Bernard-Marty C, Nogaret JM, Piccart M, Larsimont D.

Crit Rev Oncol Hematol. 2008 Jul;67(1):80-92. doi: 10.1016/j.critrevonc.2007.12.008. Epub 2008 Mar 3.

PMID:
18313937
18.

HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer.

Azambuja E, Durbecq V, Rosa DD, Colozza M, Larsimont D, Piccart-Gebhart M, Cardoso F.

Ann Oncol. 2008 Feb;19(2):223-32. Epub 2007 Sep 14. Review.

PMID:
17872901
19.

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.

de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M.

Br J Cancer. 2007 May 21;96(10):1504-13. Epub 2007 Apr 24.

20.

p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.

Di Leo A, Tanner M, Desmedt C, Paesmans M, Cardoso F, Durbecq V, Chan S, Perren T, Aapro M, Sotiriou C, Piccart MJ, Larsimont D, Isola J; TAX 303 translational study team.

Ann Oncol. 2007 Jun;18(6):997-1003. Epub 2007 Mar 17.

PMID:
17369602
21.

Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation.

Journe F, Laurent G, Chaboteaux C, Nonclercq D, Durbecq V, Larsimont D, Body JJ.

Breast Cancer Res Treat. 2008 Jan;107(1):49-61. Epub 2007 Feb 28.

PMID:
17333335
22.

Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).

Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, Leroy JY, Borms M, Vindevoghel A, Jerusalem G, D'Hondt V, Dirix L, Canon JL, Richard V, Cocquyt V, Majois F, Reginster M, Demol J, Kains JP, Delree P, Keppens C, Sotiriou C, Piccart MJ, Cardoso F.

Eur J Cancer. 2007 Mar;43(4):725-35. Epub 2007 Jan 23.

PMID:
17251007
23.

Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.

Cardoso F, Durbecq V, Laes JF, Badran B, Lagneaux L, Bex F, Desmedt C, Willard-Gallo K, Ross JS, Burny A, Piccart M, Sotiriou C.

Mol Cancer Ther. 2006 Dec;5(12):3042-51. Epub 2006 Dec 5.

24.

The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.

Mano MS, Rosa DD, De Azambuja E, Ismael GF, Durbecq V.

Cancer Treat Rev. 2007 Feb;33(1):64-77. Epub 2006 Nov 17. Review.

PMID:
17113234
25.

Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.

Dal Lago L, Durbecq V, Desmedt C, Salgado R, Verjat T, Lespagnard L, Ma Y, Veys I, Di Leo A, Sotiriou C, Piccart M, Larsimont D.

Mol Cancer Ther. 2006 Oct;5(10):2572-9.

26.

Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients.

Desmedt C, Ouriaghli FE, Durbecq V, Soree A, Colozza MA, Azambuja E, Paesmans M, Larsimont D, Buyse M, Harris A, Piccart M, Martiat P, Sotiriou C.

Int J Cancer. 2006 Dec 1;119(11):2539-45.

27.

Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice.

Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-Galdon M, Veys I, Cardoso F, Sotiriou C, Di Leo A, Piccart MJ, Larsimont D.

Clin Cancer Res. 2005 Jun 15;11(12):4393-9.

28.

Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer.

Cardoso F, Paesmans M, Larsimont D, Durbecq V, Bernard-Marty C, Rouas G, Dolci S, Sotiriou C, Piccart MJ, Di Leo A.

Clin Breast Cancer. 2004 Dec;5(5):364-9.

PMID:
15585074
29.

HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

Di Leo A, Chan S, Paesmans M, Friedrichs K, Pinter T, Cocquyt V, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Von Minckwitz G, Leroy JY, Durbecq V, Isola J, Aapro M, Piccart MJ, Larsimont D.

Breast Cancer Res Treat. 2004 Aug;86(3):197-206.

PMID:
15567936
30.

Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer.

Durbecq V, Desmed C, Paesmans M, Cardoso F, Di Leo A, Mano M, Rouas G, Leroy JY, Sotiriou C, Piccart M, Larsimont D.

Int J Oncol. 2004 Nov;25(5):1473-9.

PMID:
15492841
31.

Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.

Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Perren TJ, Leroy JY, Rouas G, Sotiriou C, Piccart M, Larsimont D.

Mol Cancer Ther. 2004 Oct;3(10):1207-14.

32.

Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation.

Mano MS, Awada A, Minisini A, Durbecq V, Di Leo A, Piccart M.

Breast. 2004 Aug;13(4):347-9.

PMID:
15325672
33.

Targeting the ubiquitin-proteasome pathway in breast cancer.

Cardoso F, Ross JS, Picart MJ, Sotiriou C, Durbecq V.

Clin Breast Cancer. 2004 Jun;5(2):148-57. Review.

PMID:
15245620
34.

Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.

Mano MS, Awada A, Di Leo A, Durbecq V, Paesmans M, Cardoso F, Larsimont D, Piccart M.

Gynecol Oncol. 2004 Mar;92(3):887-95.

PMID:
14984957
35.

Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.

Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy JY, Rouas G, Sotiriou C, Renard N, Richard V, Piccart MJ, Di Leo A.

Int J Oncol. 2004 Jan;24(1):201-9.

PMID:
14654958
36.

Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites.

Durbecq V, Di Leo A, Cardoso F, Rouas G, Leroy JY, Piccart M, Larsimont D.

Breast Cancer Res Treat. 2003 Feb;77(3):199-204.

PMID:
12602919
37.

Preliminary X-ray crystallographic analysis of tRNA pseudouridine 55 synthase from the thermophilic eubacterium Thermotoga maritima.

Wouters J, Tricot C, Durbecq V, Roovers M, Stalon V, Droogmans L.

Acta Crystallogr D Biol Crystallogr. 2003 Jan;59(Pt 1):152-4. Epub 2002 Dec 19.

PMID:
12499554
38.

Resistance to trastuzumab: a necessary evil or a temporary challenge?

Cardoso F, Piccart MJ, Durbecq V, Di Leo A.

Clin Breast Cancer. 2002 Oct;3(4):247-57; discussion 258-9. Review.

PMID:
12425752
39.

Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.

Di Leo A, Cardoso F, Durbecq V, Giuliani R, Mano M, Atalay G, Larsimont D, Sotiriou C, Biganzoli L, Piccart MJ.

Int J Clin Oncol. 2002 Aug;7(4):245-53. Review.

PMID:
12202978
40.

Genes of de novo pyrimidine biosynthesis from the hyperthermoacidophilic crenarchaeote Sulfolobus acidocaldarius: novel organization in a bipolar operon.

Thia-Toong TL, Roovers M, Durbecq V, Gigot D, Glansdorff N, Charlier D.

J Bacteriol. 2002 Aug;184(16):4430-41.

41.
42.

Crystal structure of isopentenyl diphosphate:dimethylallyl diphosphate isomerase.

Durbecq V, Sainz G, Oudjama Y, Clantin B, Bompard-Gilles C, Tricot C, Caillet J, Stalon V, Droogmans L, Villeret V.

EMBO J. 2001 Apr 2;20(7):1530-7.

43.

Carbamoyl phosphate synthesis: carbamate kinase from Pyrococcus furiosus.

Uriarte M, Marina A, Ramón-Maiques S, Rubio V, Durbecq V, Legrain C, Glansdorff N.

Methods Enzymol. 2001;331:236-47. No abstract available.

PMID:
11265466
44.

Preliminary structural studies of Escherichia coli isopentenyl diphosphate isomerase.

Oudjama Y, Durbecq V, Sainz G, Clantin B, Tricot C, Stalon V, Villeret V, Droogmans L.

Acta Crystallogr D Biol Crystallogr. 2001 Feb;57(Pt 2):287-8.

PMID:
11173482
45.

Aspartate carbamoyltransferase from the thermoacidophilic archaeon Sulfolobus acidocaldarius. Cloning, sequence analysis, enzyme purification and characterization.

Durbecq V, Thia-Toong TL, Charlier D, Villeret V, Roovers M, Wattiez R, Legrain C, Glansdorff N.

Eur J Biochem. 1999 Aug;264(1):233-41.

46.
47.

Supplemental Content

Loading ...
Support Center